Compounds > rupatadine
Page last updated: 2024-09-04

rupatadine and zithromax

rupatadine has been researched along with zithromax in 1 studies

Compound Research Comparison

Studies
(rupatadine)		Trials
(rupatadine)		Recent Studies (post-2010)
(rupatadine)		Studies
(zithromax)		Trials
(zithromax)		Recent Studies (post-2010) (zithromax)
11643626,9641,2633,790

Protein Interaction Comparison

ProteinTaxonomyrupatadine (IC50)zithromax (IC50)
30S ribosomal protein S6Escherichia coli K-120.3
30S ribosomal protein S7Escherichia coli K-120.3
50S ribosomal protein L15Escherichia coli K-120.3
50S ribosomal protein L10Escherichia coli K-120.3
50S ribosomal protein L11Escherichia coli K-120.3
50S ribosomal protein L7/L12Escherichia coli K-120.3
50S ribosomal protein L19Escherichia coli K-120.3
50S ribosomal protein L1Escherichia coli K-120.3
50S ribosomal protein L20Escherichia coli K-120.3
50S ribosomal protein L27Escherichia coli K-120.3
50S ribosomal protein L28Escherichia coli K-120.3
50S ribosomal protein L29Escherichia coli K-120.3
50S ribosomal protein L31Escherichia coli K-120.3
50S ribosomal protein L31 type BEscherichia coli K-120.3
50S ribosomal protein L32Escherichia coli K-120.3
50S ribosomal protein L33Escherichia coli K-120.3
50S ribosomal protein L34Escherichia coli K-120.3
50S ribosomal protein L35Escherichia coli K-120.3
50S ribosomal protein L36Escherichia coli K-120.3
30S ribosomal protein S10Escherichia coli K-120.3
30S ribosomal protein S11Escherichia coli K-120.3
30S ribosomal protein S12Escherichia coli K-120.3
30S ribosomal protein S13Escherichia coli K-120.3
30S ribosomal protein S16Escherichia coli K-120.3
30S ribosomal protein S18Escherichia coli K-120.3
30S ribosomal protein S19Escherichia coli K-120.3
30S ribosomal protein S20Escherichia coli K-120.3
30S ribosomal protein S2Escherichia coli K-120.3
30S ribosomal protein S3Escherichia coli K-120.3
30S ribosomal protein S4Escherichia coli K-120.3
30S ribosomal protein S5Escherichia coli K-120.3
30S ribosomal protein S8Escherichia coli K-120.3
30S ribosomal protein S9Escherichia coli K-120.3
50S ribosomal protein L13Escherichia coli K-120.3
50S ribosomal protein L14Escherichia coli K-120.3
50S ribosomal protein L16Escherichia coli K-120.3
50S ribosomal protein L23Escherichia coli K-120.3
30S ribosomal protein S15Escherichia coli K-120.3
50S ribosomal protein L17Escherichia coli K-120.3
50S ribosomal protein L21Escherichia coli K-120.3
50S ribosomal protein L30Escherichia coli K-120.3
50S ribosomal protein L6Escherichia coli K-120.3
30S ribosomal protein S14Escherichia coli K-120.3
30S ribosomal protein S17Escherichia coli K-120.3
30S ribosomal protein S1Escherichia coli K-120.3
50S ribosomal protein L18Escherichia coli K-120.3
50S ribosomal protein L2Escherichia coli K-120.3
50S ribosomal protein L3Escherichia coli K-120.3
50S ribosomal protein L24Escherichia coli K-120.3
50S ribosomal protein L4Escherichia coli K-120.3
50S ribosomal protein L22Escherichia coli K-120.3
50S ribosomal protein L5Escherichia coli K-120.3
30S ribosomal protein S21Escherichia coli K-120.3
50S ribosomal protein L25Escherichia coli K-120.3
50S ribosomal protein L36 2Escherichia coli K-120.3

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonijoan, R; Barbanoj, M; Carbó, ML; Donado, E; Izquierdo, I; Merlos, M; Nadal, T; Peña, J; Solans, A1

Trials

1 trial(s) available for rupatadine and zithromax

ArticleYear
Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Clinical therapeutics, 2008, Volume: 30, Issue:9

    Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Chromatography, High Pressure Liquid; Confidence Intervals; Cross-Over Studies; Cyproheptadine; Dose-Response Relationship, Drug; Drug Interactions; Female; Histamine H1 Antagonists; Humans; Loratadine; Male; Safety; Therapeutic Equivalency

2008